Dr Jagannath on Linvoseltamab vs Teclistamab in Triple-Class–Exposed R/R Myeloma

Sundar Jagannath, MBBS, director, Center of Excellence for Multiple Myeloma, professor, medicine (hematology and medical oncology), The Tisch Cancer Institute, Mount Sinai, discusses findings from an indirect comparison of linvoseltamab and teclistamab-cqyv (Tecvayli) in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Jagannath shared data from the indirect comparison at the 2024 ASCO Annual Meeting. Both linvoseltamab and teclistamab are bispecific antibodies targeting CD3 on T cells and BCMA on multiple myeloma cells. Using a matching-adjustedindirect comparison approach, patient-level data from the phase 1/2 LINKER-MM1 trial (NCT03761108) of linvoseltamab in patients with relapsed/refractory multiple myeloma and aggregate data from the phase 1/2 MajesTEC-1 trial (NCT03145181, NCT04557098) of teclistamab in this patient population were analyzed. After matching key prognostic factors, linvoseltamab elicited significantly better efficacy vs teclistamab in terms of complete response (CR) rates, progression-free survival, and time to next therapy.

Linvoseltamab is currently in development to address the needs of patients with triple-class–exposed, relapsed/refractory multiple myeloma who have undergone 3 or more prior lines of therapy, akin to the teclistamab indication, Jagannath begins. To ensure the comparability of patient cohorts in this analysis, a matching process was undertaken based on key prognostic factors identified beforehand, he says. The top 6 significant prognostic factors were identified and evaluated, he says.

Upon evaluating these efficacy outcomes, linvoseltamab was superior to teclistamab across various predetermined parameters, Jagannath explains. Subsequent analyses incorporating all identified prognostic factors reaffirmed linvoseltamab’s favorable performance, particularly in terms of overall response and depth of response, with a notable increase in CR rate, Jagannath reports.

Furthermore, linvoseltamab has a promising safety profile, he states. Specifically, it exhibits lower incidences of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome compared with other drug classes, such as CAR-T cell therapy, he explains. Jagannath concludes by stating that this favorable safety profile further underscores the potential of linvoseltamab as a valuable therapeutic option for the specified patient population.